Please assess the completion status of the following clinical trial:

Trial Title: Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants may be included if they meet all of the following inclusion criteria prior to randomization:~1. Male or female participants ≥18 years of age.~2. History of ASCVD (coronary heart disease \[CHD\], cardiovascular disease \[CVD\], or peripheral arterial disease \[PAD\]).~3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).~4. Fasting triglyceride \<4.52 mmol/L (\<400 mg/dL) at screening.~5. Calculated glomerular filtration rate \>30 mL/min by estimated glomerular filtration rate (eGFR) using standardized clinical methodology~6. Participants on statins should be receiving a maximally tolerated dose.~7. Participants not receiving statins must have documented evidence of intolerance to all doses of at least 2 different statins.~8. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a stable dose for ≥30 days before screening with no planned medication or dose change during study participation.~9. Subjects were willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures~Exclusion Criteria:~Participants will be excluded from the study if any of the following exclusion criteria apply prior to randomization:~1. New York Heart Association (NYHA) class IV heart failure.~2. Uncontrolled cardiac arrhythmia.~3. Uncontrolled severe hypertension.~4. Active liver disease.~5. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least 2 methods of highly effective contraception (failure rate less than 1% per year) (for example, combined oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, or intrauterine device) for the entire duration of the study. Exemptions from this criterion:~   1. Women \>2 years postmenopausal (defined as 1 year or longer since last menstrual period) and more than 55 years of age.~  2. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.~  3. Women who are surgically sterilized at least 3 months prior to enrollment.~6. Males who are unwilling to use an acceptable method of birth control during the entire study period (such as condom with spermicide).~7. Treatment with other investigational products or devices within 30 days or 5 half-lives of the screening visit, whichever is longer.~8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inclisiran (Type: EXPERIMENTAL): Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
- Saline Solution (Type: PLACEBO_COMPARATOR): Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete